《药理学现况》(Cophar)发表了权威、全面和系统的评论。Cophar帮助专家了解药理学和药物发现的最新进展,并提供清晰易读的综合信息。专家作者从今天出版的不断扩大的信息量中注释最有趣的论文,节省了宝贵的时间,并使读者对重要领域有了深刻的了解。Cophar是当前意见和研究(Co+Re)系列期刊的一部分,是新的初级研究、开放获取期刊、药理学和药物发现(Crphar)的当前研究的伙伴。Cophar将药理学的主题分成主题部分,每一部分每年进行一次回顾。每个部分的空间大小与其重要性有关。主题包括神经科学、心血管和肾脏、呼吸、肌肉骨骼、癌症、免疫调节、抗感染、新技术、胃肠、内分泌和代谢疾病。该杂志以爱思唯尔在科学出版方面的卓越声誉和长期致力于传播以改善人类健康为目标的可再生生物医学研究为基础。
Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR).COPHAR divides the subject of pharmacology into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance. Themes include neurosciences; cardiovascular and renal; respiratory; musculoskeletal; cancer; immunomodulation; anti-infectives; new technologies; gastrointestinal; endocrine; and metabolic diseases.The journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.
SCI热门推荐期刊 >
SCI常见问题 >
职称论文常见问题 >
EI常见问题 >